"The Wegovy pill-which has been in clinical trials for over two years and was approved by the FDA on December 22-is the first and only oral GLP-1 for weight loss in adults available in the U.S. According to a press release from Novo Nordisk, the pill hit the market on January 5 at more than 70,000 U.S. pharmacies and several popular telehealth providers. Per a KFF health tracking poll released in November, one in eight Americans were already taking a GLP-1 for weight-loss."
""We know there are people who are interested in addressing their weight but have been waiting on the sidelines for a medicine that was right for them," Ed Cinca, Novo Nordisk's senior vice president of marketing & patient solutions, said in the press release. For many of them, he added, that wait is over. As of this writing, Novo Nordisk's stock is up about 4% since the announcement."
Novo Nordisk launched an oral version of Wegovy, the first FDA-approved oral GLP-1 for adult weight loss, which became available on January 5 at over 70,000 U.S. pharmacies and multiple telehealth providers. The pill completed clinical trials over two years and is offered in 1.5 mg (starter), 4 mg, 9 mg, and 25 mg doses. The medication requires a prescription. Self-pay pricing starts at $149 per month for 1.5 mg; the 4 mg dose is $149 monthly through April 15, 2026, then $199 monthly; the 25 mg dose is $299 monthly. A recent KFF poll estimated one in eight Americans were already using a GLP-1, and Novo Nordisk's stock rose about 4% after the launch.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]